|
.Usually endometrial cancers are discovered in FIGO stage 1. One
study showed only 3.8% are diagnosed at stage 4. This low
incidence of stage 4 endometrial cancer contribute to the poor
experience of gynaecologists treating these cases.
As such, guidelines to therapeutic considerations
are mainly based on logical reasoning. The rationale . of pelvic
treatment in patients with extrapelvic disease is to improve the
patient's chances of being cured by subsequent therapy. Pelvic
treatment not only relieve local symptoms such as vaginal
bleeding, discharge, pain, impending bowel obstruction but also
results in an overall improvement in quality of life. Generally,
radiotherapy is not useful in treating extrapelvic disease.
Systemic treatment with progestational agents in patients with
metastatic endometrial cancer is logical. For lung metastasis
complete remission can be achieved in 20 to 45 % of the cases. As
for the role of non hormonal cytotoxic chemotherapy, recent
reports have demonstrated encouraging results with 5-flourauracil,
adriamicin, and cis-platinum.
Only results from prospective randomized trials
can identify the most effective drug or combinations of drugs for
patients with advanced or reccurent endometrial carcinoma who do
not respond to hormonal treatment
About the author
DR SOON is a medical practitioner. He holds four degrees. MBBS
(University of Malaya), MBA (University of East Asia), LLB (Hons)
(University of Wolverhampton), Master of Medicine (Edith Cowan
University
:
Dr SOON is the owner of AskMyVisitor.com and MyScriptDoctor.com
where you can find the most up-to-date advice and information
on
many medical, health and lifestyle topics.
|
